Scarica l'app Stockscreener
1.735
6.12%
0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.635
Aprire:
$1.66
Volume 24 ore:
174.11K
Relative Volume:
0.65
Capitalizzazione di mercato:
$56.60M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.5773
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-12.81%
1M Prestazione:
-13.68%
6M Prestazione:
-28.60%
1 anno Prestazione:
+49.57%
Intervallo 1D:
$1.62
$1.79
Intervallo di 1 settimana:
$1.55
$2.02
Portata 52W:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.7327 | 56.60M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.07 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.06 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.14 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
541.09 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.56 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Northern Trust Corp Raises Holdings in Banco Bradesco S.A. (NYSE:BBDO) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Has $226,000 Position in LightPath Technologies, Inc. (NASDAQ:LPTH) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Purchased by Northern Trust Corp - Defense World
i-80 Gold Corp. (NYSE:IAUX) Receives $3.50 Average PT from Brokerages - Defense World
Northern Trust Corp Increases Stock Holdings in PetMed Express, Inc. (NASDAQ:PETS) - Defense World
Northern Trust Corp Purchases 10,466 Shares of United-Guardian, Inc. (NASDAQ:UG) - Defense World
Northern Trust Corp Grows Stock Holdings in Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) - Defense World
Northern Trust Corp Increases Stock Position in NeueHealth, Inc. (NYSE:NEUE) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - The Manila Times
Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq
Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan
Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com
Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus
Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga
CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister
HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus
Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World
Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks
Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq
Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus
Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gain Therapeutics Inc Azioni (GANX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):